Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.44 USD
−27.78 M USD
1.50 M USD
13.99 M
About Oncocyte Corporation
Sector
Industry
CEO
Joshua Riggs
Website
Headquarters
Irvine
Founded
2009
FIGI
BBG00JVRGJL2
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0KCC is 2.10 USD — it has increased by 1.02% in the past 24 hours. Watch ONCOCYTE CORP COM NPV (POST REV SPLIT) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ONCOCYTE CORP COM NPV (POST REV SPLIT) stocks are traded under the ticker 0KCC.
We've gathered analysts' opinions on ONCOCYTE CORP COM NPV (POST REV SPLIT) future price: according to them, 0KCC price has a max estimate of 4.25 USD and a min estimate of 4.00 USD. Watch 0KCC chart and read a more detailed ONCOCYTE CORP COM NPV (POST REV SPLIT) stock forecast: see what analysts think of ONCOCYTE CORP COM NPV (POST REV SPLIT) and suggest that you do with its stocks.
0KCC reached its all-time high on Feb 19, 2021 with the price of 127.38 USD, and its all-time low was 2.32 USD and was reached on Nov 2, 2023. View more price dynamics on 0KCC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0KCC stock is 34.76% volatile and has beta coefficient of 0.26. Track ONCOCYTE CORP COM NPV (POST REV SPLIT) stock price on the chart and check out the list of the most volatile stocks — is ONCOCYTE CORP COM NPV (POST REV SPLIT) there?
Today ONCOCYTE CORP COM NPV (POST REV SPLIT) has the market capitalization of 42.59 M, it has increased by 2.30% over the last week.
Yes, you can track ONCOCYTE CORP COM NPV (POST REV SPLIT) financials in yearly and quarterly reports right on TradingView.
ONCOCYTE CORP COM NPV (POST REV SPLIT) is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
0KCC earnings for the last quarter are −0.40 USD per share, whereas the estimation was −0.44 USD resulting in a 7.99% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about ONCOCYTE CORP COM NPV (POST REV SPLIT) earnings.
ONCOCYTE CORP COM NPV (POST REV SPLIT) revenue for the last quarter amounts to 115.00 K USD, despite the estimated figure of 178.33 K USD. In the next quarter, revenue is expected to reach 101.67 K USD.
0KCC net income for the last quarter is −13.49 M USD, while the quarter before that showed −4.53 M USD of net income which accounts for −197.86% change. Track more ONCOCYTE CORP COM NPV (POST REV SPLIT) financial stats to get the full picture.
No, 0KCC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 28, 2024, the company has 46.00 employees. See our rating of the largest employees — is ONCOCYTE CORP COM NPV (POST REV SPLIT) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ONCOCYTE CORP COM NPV (POST REV SPLIT) EBITDA is −21.57 M USD, and current EBITDA margin is −1.37 K%. See more stats in ONCOCYTE CORP COM NPV (POST REV SPLIT) financial statements.
Like other stocks, 0KCC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ONCOCYTE CORP COM NPV (POST REV SPLIT) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ONCOCYTE CORP COM NPV (POST REV SPLIT) technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ONCOCYTE CORP COM NPV (POST REV SPLIT) stock shows the sell signal. See more of ONCOCYTE CORP COM NPV (POST REV SPLIT) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.